Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors

Geoffrey I. Shapiro, Raoul Tibes, Michael S. Gordon, Bryan Y. Wong, Joseph Paul Eder, Mitesh J. Borad, David S. Mendelson, Nicholas J. Vogelzang, Bruno R. Bastos, Glen J. Weiss, Cristian Fernandez, William Sutherland, Hitoshi Sato, William E. Pierceall, David Weaver, Scott Slough, Ernesto Wasserman, Donald W. Kufe, Daniel Von Hoff, Takumi KawabeSunil Sharma

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences